Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term therapeutic use. Found 398 abstracts

no pagination
Wang L, Yorke E, Desobry G, Chui CS. Dosimetric advantage of using 6 MV over 15 MV photons in conformal therapy of lung cancer: Monte Carlo studies in patient geometries. J Appl Clin Med Phys. 2002 Jan;3(1):51-9.
Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug;20(15):3317-27.
Adams GP, Weiner LM. Radioimmunotherapy of solid tumors: from fairytale to reality. Cancer Biother Radiopharm. 2001 Feb;16(1):9-11.
Baselli EC, Greenberg RE. Maintenance therapy for superficial bladder cancer. Oncology (Huntingt). 2001 Jan;15(1):85-8; discussion 88-91.
Bast RC, Mills GB, Young RC. Translational research--traffic on the bridge. Biomed Pharmacother. 2001 Nov;55(9-10):565-71.
Bookman MA. Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2001 Jan;11 Suppl 1:42-51.
Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol. 2001 Oct;31(10):3016-25.
Cianfrocca M, Goldstein LJ. Operable breast cancer. Current treatment options in oncology. 2001 Apr;2(2):157-67.
Clapper ML, Chang WC, Meropol NJ. Chemoprevention of colorectal cancer. Curr Opin Oncol. 2001 Jul;13(4):307-13.
Cohen RB, Dittrich KA. Anti-TNF therapy and malignancy - a critical review. Can J Gastroenterol. 2001 Jun;15(6):376-84.
Cornfeld MJ, Jadwin A, O'Grady P, Babb J, Engstrom PF. Feasibility of assessing quality in medical oncology practices. Cancer Pract. 2001 Sep;9(5):231-5.
Fleming GF, Fowler JM, Waggoner SE, Copeland LJ, Greer BE, Horowitz I, Sutton G, Schilder RJ, Fracasso PM, Ball HG, McGuire WP. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 2001 Feb 15;19(4):1021-9.
Gabrielson EW, Pinn ML, Testa JR, Kuhajda FP. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res. 2001 Jan;7(1):153-7.
Haas NB. Can chemotherapy alter the course of prostate cancer?. Semin Urol Oncol. 2001 Aug;19(3):212-21.
Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, Rogatko A, Babb J, Minnitti C, Flinker D, Gillon T, Hudes G. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology. 2001 Jul;58(1):59-64.
Held-Warmkessel J. Treatment of advanced prostate cancer. Semin Oncol Nurs. 2001 May;17(2):118-28.
Holland J. New treatment modalities in radiation therapy. J Intraven Nurs. 2001 Mar;24(2):95-101.
Horwitz EM, Pinover WH, Hanks GE. Re: Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J Urol. 2001 Apr;165(4):1224.
Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):947-56.
Jagasia MH, Langer CJ, Johnson DH, Yunus F, Rodgers JS, Schlabach LL, Cohen AG, Shyr Y, Carbone DP, Devore RF. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clin Cancer Res. 2001 Jan;7(1):68-73.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term therapeutic use

Human therapeutic use drug therapy pathology Male Female radiotherapy Antineoplastic Combined Chemotherapy Protocols administration & dosage Prostatic Neoplasms US Gov't Support-PHS Non-US Gov't Support Survival Analysis Middle Age Breast Neoplasms analogs & derivatives Neoplasms Animal Paclitaxel therapy adverse effects antagonists & inhibitors Aged drug effects Monoclonal Antibodies Combined Modality Therapy Hormonal Antineoplastic Agents methods Disease Progression Adjuvant Chemotherapy prevention & control Mice Cisplatin Disease-Free Survival Antineoplastic Agents Lung Neoplasms Neoplasm Staging Feasibility Studies Adult trends Medical Oncology pharmacology adverse enzymology Doxorubicin Adenocarcinoma Tamoxifen surgery effects Oral Administration Estramustine Drug Administration Schedule Prognosis Randomized Controlled Trials Cultured Tumor Cells Brachytherapy Treatment Outcome Radiometry immunology Iodine Radioisotopes Computer-Assisted Radiotherapy Planning Radiotherapy Dosage mortality Radioimmunotherapy Antifungal Antibiotics epidemiology Research Camptothecin Urologic Surgical Procedures 80 and over Aged diagnostic use Remission Induction Gastrointestinal Agents Transitional Cell Carcinoma Postmenopause Monte Carlo Method Local Neoplasm Recurrence Dose Fractionation Carcinoma Granulocyte Colony-Stimulating Factor Aromatase Molecular Weight Non-Small-Cell Lung Carcinoma Bladder Neoplasms Proportional Hazards Models pharmacokinetics dosage Animal Disease Models Immunoglobulin Fragments Nude Mice IgG Receptors etiology Edema Prospective Studies biosynthesis Non-Steroidal Anti-Inflammatory Agents cytology Neoplasm Antibodies Mitoxantrone Radiotherapy Cerulenin statistics & numerical data Practice Guidelines Antineoplastic Antibiotics Chimeric Proteins Drug Design Peripheral Nerves Methotrexate US Gov't Support-Non-PHS Neoplasm Drug Resistance Fluorouracil United States Liposomes Neoplasm Transplantation CD56 Antigens statistics & Androgen Antagonists Expert Testimony Carcinoembryonic Antigen Mesothelioma Photons Evidence-Based Medicine Carboplatin Cytokines chemically induced Treatment Failure Diet Therapy Quality of Life Paraffin Embedding Goserelin physiology Drug Dose-Response Relationship Oncologic Nursing Neoplasm Antigens Vitamins Mesothelial Neoplasms Interleukin-2 Anaphylaxis Conformal Radiotherapy standards Mitomycin Natural Killer Cells radionuclide imaging secondary Liver Diseases erbB-2 Receptor Hormone-Dependent Neoplasms Cyclooxygenase Inhibitors National Institutes of Health (US) Fluorine Radioisotopes
Last updated on Friday, January 03, 2020